Form D · Other
Compass Therapeutics, Inc.
Cambridge, MA · CIK 0001738021
Offering snapshot reported Jul 1, 2020 · SEC filing
- Reported sold
- $195M Offering amount: $195M
- Investors reported
- 114 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 17, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 1, 2020 | Initial | $195,276,780 | No comparison | 114 | SEC filing |
| Jul 1, 2020 | Initial | $60,482,210 | No comparison | 110 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-370112
Source: Form D, filed Jul 1, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vered Bisker Leib | Executive |
| Philip Ferneau | Director |
| Carl L. Gordon | Director |
| Thomas J. Schuetz | Director, Executive |
| Stephen P. Squinto | Director |
| Julie Sunderland | Director |
Issuer details
Industry: Other (See others in industry)
Address:
245 First Street, 3 Rd Floor
Cambridge, MA, 02142
Cambridge, MA, 02142